Rani Therapeutics announced that it has entered into a collaboration with MedImmune, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules. Upon successful completion of the feasibility studies, AstraZeneca and MedImmune will have the right to enter into a more extensive collaboration with Rani.